Bortezomib in the management of multiple myeloma

Review

(6923) Total Article Views

Authors: Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Published Date September 2009 Volume 2009:1 Pages 107 - 117

DOI: http://dx.doi.org/10.2147/CMAR.S4555

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G Richardson

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.

Keywords: multiple myeloma, bortezomib, stem cell transplantation, peripheral neuropathy

Other articles by Dr Paul Richardson

Readers of this article also read: